Cost-Effectiveness of Lopinavir/Ritonavir Versus Nelfinavir As the First-Line Highly Active Antiretroviral Therapy Regimen for HIV Infection
Authors:
- 1 October 2004
- journal article
- research article
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 5 (5) , 294-304
Abstract
Purpose: Selecting the optimal treatment regimen for antiviral-naïve patients may be difficult, given the concern about the antiviral activity, the development of drug resistance, and the increase in drug costs. This study evaluates the costs and effectiveness of using lopinavir/ritonavir (LPV/r) vs. nelfinavir (NFV), both coadministered with stavudine and lamivudine, as the first HAART regimen in treating HIV patients, based on the results from the published clinical trial M98-863. Method: A Markov model was developed using a combination of viral load (VL) and CD4 count as surrogate markers to define health states. VL and CD4 count data from the 48-week analysis of the clinical trial were used as measures of effect. The impact of resistance difference between NFV and LPV/r was also examined. Results: Over the first 5 years, the model estimated that LPV/r could save $3,461 per patient in total HIV care costs compared with NFV. If the resistance advantage of LPV/r was taken into account, the cost savings by LPV/r increased to $5,546. For longer term projection, without considering the resistance difference, the incremental cost-effectiveness ratio (CER) for LPV/r vs. NFV was $6,653 per quality-adjusted life-year (QALY). This CER compares favorably to therapies for HIV disease and for common drug treatments for other conditions and is well within accepted thresholds for health policy makers. Conclusion: When treatment options are being considered, this study suggests that use of LPV/r in the first antiretroviral regimen, as compared to NFV, is cost-effective based on improved efficacy and resistance.Keywords
This publication has 14 references indexed in Scilit:
- Absolute CD4 Vs. CD4 Percentage for Predicting the Risk of Opportunistic Illness in HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patientsAIDS, 2004
- Incidence of Resistance in a Double‐Blind Study Comparing Lopinavir/Ritonavir Plus Stavudine and Lamivudine to Nelfinavir plus Stavudine and LamivudineThe Journal of Infectious Diseases, 2004
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV InfectionNew England Journal of Medicine, 2002
- Prophylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii PneumoniaArchives of internal medicine (1960), 2002
- Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir TherapyAntiviral Therapy, 2002
- A Monte Carlo Simulation for Modelling Outcomes of AIDS Treatment RegimensPharmacoEconomics, 2002
- Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databasesAIDS, 2001
- The Cost Effectiveness of Combination Antiretroviral Therapy for HIV DiseaseNew England Journal of Medicine, 2001
- Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/??l in 5 European CountriesPharmacoEconomics, 1994